Akèy › Kansè vejik › Kalifòni › Orange
Etid klinik pou Kansè vejik nan Orange, CA
12 etid pou Kansè vejik ap chèche patisipan nan sit nan ak bò kote Orange (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy
Ap rekriteFaz 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
Ap rekriteFaz 2
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Ap rekriteFaz 1/2
- UC Irvine Health, Orange
A Study of Vepugratinib (LY3866288) in Participants With Cancer in the Urinary Tract
Ap rekriteFaz 3
- University of California, Irvine (UCI) Health - UC Irvine Medical Center, Orange
Phase 2 Study to Evaluate Safety and Efficacy of Cretostimogene Grenadenorepvec in High-Risk NMIBC
Ap rekriteFaz 2
- University of California, Irvine, Orange
Safety and Efficacy Study of Intravesical Instillation of TARA-002 in Adults With High-grade Non-muscle Invasive Bladder Cancer
Ap rekriteFaz 2
- University of California Irvine Medical Center, Orange
FORAGER-1: A Study of Vepugratinib (LY3866288; LOXO-435) in Participants With Cancer With a Change in a Gene Called FGFR3
Ap rekriteFaz 1
- University of California - Irvine, Orange
Patient-Derived Xenografts to Reduce Cancer Health Disparities
Ap rekriteEtid obsèvasyon
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
Ap rekriteFaz 3
- UC Irvine Health/Chao Family Comprehensive Cancer Center, Orange
A Study of Disitamab Vedotin Alone or With Pembrolizumab in Urothelial Cancer That Expresses HER2
Ap rekriteFaz 2
- UC Irvine Health, Orange
Repurposing Riluzole for Cancer-Related Cognitive Impairment: A Pilot Trial
Ap rekriteFaz 2
- Chao Family Comprehensive Cancer Center, University of California Irvine, Orange
SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry
Ap rekriteEtid obsèvasyon
- Massive Bio SYNERGY-AI site, Orange
Etid Kansè vejik nan lòt vil
- New York City, NY35 etid
- Nashville, TN31 etid
- Houston, TX31 etid
- Dallas, TX27 etid
- Boston, MA26 etid
- Washington, DC26 etid
- Los Angeles, CA24 etid
- Baltimore, MD24 etid
- St. Louis, MO22 etid
- Philadelphia, PA21 etid
- Seattle, WA21 etid
- Edison, NJ21 etid
Lòt etid nan Orange
- Kansè Poumon ki pa ti selil25 etid
- Kansè Metastatik20 etid
- Kansè kolorektal16 etid
- Kansè ovè16 etid
- Kansè pankreyas15 etid
- Kansè nan tete14 etid
- Kansè poumon14 etid
- Kansè pwostat14 etid
- Kansè fwa (Kasinòm epatoselilè)14 etid
- Melanom14 etid
- Leksemi mieloïd egi13 etid
- Kansè (tout kalite)13 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 5, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.